Joint MHRA and ABPI training: Making the case for UK medicines manufacturing

The Making the case for UK medicines manufacturing course will take place on 2 March at The Royal Society of Medicine in London

This joint event will be run by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Association of the British Pharmaceutical Industry (ABPI) and will illustrate, through evidence-based examples, the benefit of the manufacturing “ecosystem” in the UK according to the MHRA.

Gerald Heddell, director of inspection, enforcement and standards, MHRA said: “Regulation is often misunderstood. Here in the UK it’s progressive, pragmatic and supportive and crucial in making the UK competitive in a global market.

“’Making the case for UK medicines’ offers a great opportunity for senior leaders in manufacturing to find out more about what we and wider UK government can offer.”

The event will enable attendees to learn about the UK’s regulatory environment, understand how to utilise a skilled workforce  and discover more about the fiscal flexibilities that help make the UK a competitive proposition for manufacturing in the pharmaceutical and service industry.

Ian McCubbin, senior vice president, North America, Japan and global pharma supply – GMS, GlasxoSmithKline said: “The UK manufacturing ‘ecosystem’ offers a hugely compelling environment.

“Our skilled workforce, pragmatic regulation and favourable tax options add up to ensure that facilities based in the UK should be part of every leading pharmaceutical company’s manufacturing network, but we are at a cross road and we will need to work together to succeed.”

To register for the event, click here.